Agoracom Blog Home

Posts Tagged ‘MMJ’

« Older Entries
Newer Entries »

Tetra Bio-Pharma $TBP.ca Initiates Enrollment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:58 AM on Wednesday, April 4th, 2018

Logo tetrabiopharma rgb web

  • Announced the initiation of screening and enrollment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain
  • Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2

1st Canadian Cannabis Smokable Pellet Study 1st Step Towards Pharmaceutical Distribution of Cannabis

OTTAWA, ONTARIO–(April 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.

Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2.

PPP001 aims to be the first smokable cannabis for advanced cancer pain available under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

“This is a significant milestone in the lead product of our strong pipeline of cannabinoid-based drugs targeting patients with advanced pain,” said Guy Chamberland, Tetra’s CEO and CSO. “The launch of the Phase 3 clinical trial will be used to support the marketing application of PPP001 smokable pellet that is followed by four other cannabinoid-based products that we are developing using different delivery systems such as oral tablets, eye drops, topical ointments and oral capsules of cannabis oil.”

On February 28th, 2018, Santé Cannabis received authorization from the Office of Controlled Substances to use PPP001 (controlled substance) for the Phase 3 clinical trial. This authorization granted the Principal Investigator of the Phase 3 trial, Dr. Antonio Vigano, exemption from the application of several provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations thereby allowing the investigator to proceed with the clinical study of PPP001 in advanced cancer patients. In addition, the exemption allows Santé Cannabis to store and dispense the study medication directly to the patients, a process not permitted by Licensed Producers under the ACMPR.

“We are performing the first large study of the safety and efficacy of a dried cannabis smoked drug in advanced cancer patients,” added Guy Chamberland. “Over the next month Tetra will expand the trial by working with other clinics across Canada. Most importantly, we believe this multisite study has the potential to change the current vision of the use of smoked cannabis as an effective palliative care therapy of patients with advanced cancer.”

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Initiates Enrollment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study $AERO $CBDS $CGRW $APH.ca $GBLX

Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 5:10 PM on Tuesday, April 3rd, 2018
  • Medical marijuana could help quell the ongoing opioid epidemic, a pair of new studies contends.
  • Opioid prescriptions tend to decrease in U.S. states that adopt medical marijuana laws or legalize recreational use of pot, two different research teams have concluded.

The studies couldn’t prove cause and effect. But one study found that opioids dispensed through Medicare’s prescription drug plan decreased significantly if people had access to medical pot dispensaries or were allowed to grow marijuana for their own use.

“We had about a 14.5 percent reduction in opiate use when states turned on dispensaries, and about a 7 percent reduction in opiate use when states turned on home cultivation-based cannabis laws,” said researcher David Bradford, chairman of public policy at the University of Georgia School of Public and International Affairs.

The other study, led by researcher Hefei Wen, from the University of Kentucky College of Public Health, found a decrease in opioid prescriptions covered by Medicaid in states that legalized either medicinal or recreational pot.

Both types of laws were linked to about a 6 percent decline in opioid prescribing, researchers reported.

“We do think there’s good reason to be hopeful that cannabis might be one tool out of many we could use to address the opioid epidemic,” Bradford said.

Drug overdoses killed nearly 64,000 Americans in 2016, with two-thirds of deaths involving a prescription or illicit opioid, the U.S. Centers for Disease Control and Prevention reported last week. Overdose deaths rose 21.5 percent in 2016, a much sharper spike than the 11.4 percent increase seen the previous year.

At this point, 30 states and the District of Columbia have laws legalizing some form of marijuana use, including eight states that have legalized recreational use.

Studies have found medical pot is effective in treating chronic pain, Bradford said. In 2017, the prestigious National Academies of Sciences, Engineering and Medicine issued a report concluding that pot can significantly reduce pain symptoms.

Both research teams suspected that if this were true, then medical marijuana might ease opioid use in people with chronic pain.

To investigate this theory, the investigators turned to recent data from the federal insurance programs Medicare and Medicaid. They compared opioid prescribing patterns between states with medical or recreational pot and those that have taken a hard line against weed.

An average state filled 23 million daily doses of opioids through Medicare’s prescription drug plan between 2010 and 2015, Bradford’s team found.

But states with medical pot dispensaries filled 3.7 million fewer daily doses, and states with home cultivation filled 1.8 million fewer doses, they said.

Results did vary based on the type of opioid, however. Medical pot was linked to reductions in hydrocodone, morphine and fentanyl prescriptions, but not to prescriptions for oxycodone, Bradford said. The second study found a similar effect among people covered by Medicaid.

The two studies were published online April 2 in JAMA Internal Medicine.

“I think at this point, with patients dying every day as a result of opioid use disorder, we need to consider all possible solutions to the crisis,” said Dr. Kevin Hill, director of addiction psychiatry at Beth Israel Deaconess Medical Center in Boston and an assistant professor of psychiatry at Harvard Medical School. “Papers like these two suggest that cannabis may play a role.”

He said these studies and others offer strong support for anecdotal evidence from patients who report they need fewer opioids for chronic pain when they are put on medical cannabis. Hill wrote an editorial that accompanied the two articles.

At the same time, Hill says medical marijuana should not be given a lead role in treating chronic pain. Instead, it should be a back-up option for patients who are struggling to manage pain and who could be in danger of addiction.

“I think it’s hard to deny that there is a growing body of evidence that suggests a role for cannabis in treating chronic pain, but it’s not the level where it would be a first-line or even second-line treatment,” Hill said.

Source: https://www.cbsnews.com/news/could-medical-marijuana-help-curb-the-opioid-crisis/

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA

Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:09 PM on Tuesday, April 3rd, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO)
  • Appointment is effective immediately

OTTAWA, ONTARIO–(April 3, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.

Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra since June 2016. He has over 23 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He worked more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.

Tetra’s former CEO, Bernard Fortier, left the corporation today thereby terminating his role as Chief Executive Officer and member of the Board of Directors.

“We are thankful for Bernard’s contributions to Tetra’s activities,” stated André Rancourt, Chairman of the Board. “Guy’s role as interim CEO will be a tremendous asset at this stage of Tetra’s growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation.”

Chamberland will serve as interim Chief Executive Officer while the Board of Directors conducts a search for a new Chief Executive Officer.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces Appointment of Laurens Feenstra, Branden Spikes and Don Nickless to Board of Directors $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:59 AM on Wednesday, March 28th, 2018

Nlogo

  • Nominees and proposed board members have served in critical roles at Google, SpaceX and Seagram’s International
  • Bringing an intangible amount of value in helping advance the Company’s technology through innovation
  • Having individuals of this pedigree join Namaste at this point in the business cycle provides immediate legitimacy to the company and will help expedite Namaste’s plans to continue on the path of revolutionizing the cannabis industry

VANCOUVER, British Columbia, March 28, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that following the company’s Annual General Meeting of shareholders (“AGM”), which was held at the law offices of Gowling WLG (Canada) LLP on Tuesday, March 27, 2018, the Company has appointed Branden Spikes, Laurens Feenstra and Donald William Nickless (the “Board Appointees”) for positions on Namaste’s 2018 board of directors. The Board Appointees mark a pivotal milestone for Namaste in solidifying the board and supporting the Company’s future growth within the cannabis industry. The Nominees and proposed board members have served in critical roles at Google, SpaceX and Seagram’s International, and bring an intangible amount of value in helping advance the Company’s technology through innovation.

Namaste has been very selective in the appointment in these directors, as it looks to expand on its already impressive list of products and services. Each appointee brings an incredible amount of expertise in their respective discipline, and Namaste believes their experience will help further differentiate Namaste within the cannabis market, as an innovator in the space. Having individuals of this pedigree join Namaste at this point in the business cycle provides immediate legitimacy to the company and will help expedite Namaste’s plans to continue on the path of revolutionizing the cannabis industry.

The Nominees’ bios and experience are outlined below:

Laurens Feenstra – Laurens Feenstra is currently Product Manager at Waymo, formerly known as Google’s self-driving car project. Prior to Waymo, he worked on some of Google’s most well-known products such as Search, Chromebooks, and Android. As a strategy consultant at McKinsey & Company, he has helped large media, banking and government clients become data analytics-driven companies. Mr. Feenstra holds degrees in Human-Computer Interaction and Artificial Intelligence from University of Groningen in the Netherlands, and was a visiting researcher on “Intelligent Tutoring Systems” at Carnegie Mellon University. When not working on the latest technology, he organizes small electronic music festivals and runs a Burning Man camp.

Branden Spikes – Branden Spikes, considered as “Elon Musk’s most trusted lieutenant” by Venture Beat, worked side by side with Musk for over 15 years and helped pioneer ground breaking technologies at SpaceX, Tesla, and PayPal. He was the CIO of SpaceX for ten years and was instrumental in setting up the information systems at Tesla Motors during its formative years after having served as Director of IT at PayPal. Spikes then founded Spikes Security in 2012, with a mission to solve the most pressing cybersecurity challenge, browser malware and served as its CEO until it merged with Aurionpro in 2017. Mr. Spikes is an investor, advisor and a technology evangelist.

Donald William Nickless – Mr. Nickless graduated from Macdonald College of McGill University with a BSc in Agriculture. Mr. Nickless then worked for thirty plus years working for the Seagram Company Limited, beginning as a front-line supervisor in manufacturing, progressing through various Department Head positions to the manager of the Company’s largest Canadian plant. Subsequent, Mr. Nickless held various positions that culminated in the appointment to Executive Vice President of Manufacturing, Seagram Americas with responsibility for Manufacturing Operations in the US, Canada, and South America. Mr. Nickless is now retired and living in Vermont as a “Gentleman Farmer”.

In connection with these nominations, Peter Simeon and Philip van den Berg have stepped down from the Company’s board of directors.

We would also like to thank Peter Simeon and Philip van den Berg for serving on the Board.  Peter will continue to serve as legal counsel and corporate secretary to the Company and Philip will continue to serve as Chief Financial Officer.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments, “I’ve always believed that successful companies are the direct by-product of building exceptional teams. The appointment of Branden Spikes, Laurens Feenstra and Donald William are a testament to that belief, and I am extremely excited to have them join our team. These Nominees further strengthen our corporate structure as we continue to build the foundation of our company, as we look to create a unique identity in the cannabis space through innovation.  To date, Namaste has demonstrated its commitment to innovation through the adoption and implementation of many one-of-a-kind initiatives, and we fully intend on taking that philosophy to the next level with the addition of these highly experienced and well respected individuals.  As the cannabis market continues to evolve at a rapid pace, we are of the opinion that Namaste must continue to come up with inventive ways to appeal to cannabis patients on a global scale.   We believe collectively that these individuals  will help facilitate future growth opportunities  and help set Namaste apart  from others looking to capitalize on this exciting industry.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Appointment of Laurens Feenstra, Branden Spikes and Don Nickless to Board of Directors $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Marijuana Company $MCOA of America Engages Eddy Pham & Company to Launch Comprehensive Hempsmart(TM) CBD Retail Marketing Campaign $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 10:23 AM on Tuesday, March 27th, 2018

15233 mcoa

  • Engaged Eddy Pham & Company (EPCO) to provide retail marketing and advertising services for its hempSMART™ branded products
  • CEO Donald Steinberg, stated, “MCOA is honored to have EPCO on as a marketing partner for our hempSMART product line. The impressive marketing strategy that EPCO will be implementing with our products will help secure hempSMART as one of the leading hemp-based cannabinoid companies in North America.”

Escondido, California–(March 27, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis company, is pleased to announce that it has engaged Eddy Pham & Company (EPCO) to provide retail marketing and advertising services for its hempSMART™ branded products.

Eddy Pham & Company is a direct to consumer full-service marketing company that will provide MCOA‘s hempSMART product line with a fully integrated, multi-channel transactional marketing campaign focused on digital advertising, infographics, content marketing, customer incentives and acquisition, a broad social media presence as well as search engine marketing and optimization that includes comprehensive research and analytics. EPCO will also be providing outsourced customer service and fulfillment services for hempSMART orders made through their campaign.

Since 1993, EPCO’s CEO, Mr. Eddy Pham has had a long and successful career managing transactional marketing campaigns. Mr. Pham has been involved in the product development, manufacturing, distribution, and campaign marketing of a number of the well-known product lines on the market. With the experience gathered from managing the manufacturing for over 160 products, EPCO is poised to help the hempSMART family of products be successful from building brand equity to overall increased sales. EPCO will utilize its partnerships within the transactional industries to help bring hempSMART to consumers who are looking for all natural, hemp-derived, full spectrum CBD and other future cannabinoid (CBC, CBG, CBN) based proprietary formulated products that are in development.

CEO Donald Steinberg, stated, “MCOA is honored to have EPCO on as a marketing partner for our hempSMART product line. The impressive marketing strategy that EPCO will be implementing with our products will help secure hempSMART as one of the leading hemp-based cannabinoid companies in North America.”

Eddy Pham states, “In over two decades of product development and transactional marketing, I can say that hempSMART produces quality products that truly work. I personally have not been this excited in a long time to work on a product line that can truly bring relief to its users.”

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Eddy Pham & Company
Eddy Pham & Company is a direct to consumer full service company that focuses on transactional marketing, product development, distribution, and operational campaign management. EPCO has branded and launched over 160 recognized and successful brands over the last 25 years. The company offers a collection of end to end services spanning various media verticals focusing on revenue enhancement.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company $MCOA of America Engages Eddy Pham & Company to Launch Comprehensive Hempsmart(TM) CBD Retail Marketing Campaign $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces Signing of a Medical Cannabis Product Acquisition Agreement With Colombian Licensed Producer Clever Leaves $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:38 AM on Monday, March 26th, 2018

Nlogo

  • Announced that it has signed a medical cannabis Product Acquisition Agreement under the Company’s wholly owned subsidiary, Cannmart Inc. with Clever Leaves
  • Supply Agreement represents further progress in Namaste securing medical cannabis supply agreements with global partners
  • Namaste, subject to approval by Health Canada, will continue to pursue importation of high-quality medical cannabis, sourced from internationally licensed producers

VANCOUVER, British Columbia, March 26, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a medical cannabis Product Acquisition Agreement (the “Supply Agreement”) under the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”), with Clever Leaves (Ecomedics S.A.S.), a vertically integrated,  licensed producer of medical cannabis in Colombia, with the assistance of Clever Leaves’ financial sponsor, Northern Swan Holdings, Inc. (“Northern Swan”). Clever Leaves has recently broken ground on a 15+ hectare Good Agricultural Collection Practices (“GACP”) compliant cultivation facility and Good Manufacturing Practices (“GMP”) Level-2 Extraction facility, leveraging high-grade technology and practices from the international pharmaceutical and cannabis industries. By 2019, development of a second Colombian cultivation site will significantly expand its cultivation capacity to meet the growing demand from domestic and international patients. This Supply Agreement represents further progress in Namaste securing medical cannabis supply agreements with global partners. Namaste, subject to approval by Health Canada, will continue to pursue importation of high-quality medical cannabis, sourced from internationally licensed producers.

Key Terms of the Supply Agreement:

  • Cannmart will submit purchase orders to Clever Leaves for medical cannabis.
  • Cannmart will import medical cannabis from Clever Leaves, subject to approval by Health Canada.
  • Cannmart will be compliant with Clever Leaves’ branding and pricing strategy.
  • Cannmart will be responsible for shipping and importation costs of the product.
  • Clever Leaves will provide Cannmart with lab test reports for each purchase in advance and in accordance with Cannmart’s requirements under Canadian regulations.
  • The packaging of products will bear the Clever Leaves brand logo.

The Supply Agreement with Clever Leaves further supports Namaste’s strategy of providing its Canadian patients with access to high-quality imported medical cannabis. The Company believes Clever Leaves’ production expertise and quality control methods will meet the highest standard of requirements necessary for importation into the Canadian market. Namaste will continue to cultivate international relationships under the guidelines set forth by Health Canada, in an attempt to position Cannmart as one of the most diverse global e-commerce platforms.

Management Commentary

Andrés Fajardo, Chairman of Clever Leaves comments; “We are thrilled to enter into a partnership with Namaste and to help carry out Colombia’s vision of becoming a leading supplier of medicinal cannabis to the world.  We believe this agreement is a validation of the professionalism of our operation, and by forging long-term win-win partnerships with best in class groups around the world, such as Namaste, we are sure to achieve this and more.”

Sean Dollinger, President and CEO of Namaste comments; “We’re very pleased to be announcing this Supply Agreement with Clever Leaves. In addition to sourcing cannabis products from domestic producers, our goal is to offer Canadian patients with the most diverse offering of medical cannabis products from high quality international cultivators. The Clever Leaves management team has proven themselves as experts in the cultivation of medical cannabis, and we are extremely excited at the potential of offering our patients access to a variety of products, which we believe will greatly benefit our patients. We remain focused on implementing this strategy, and we look forward to the launch of Cannmart. We further anticipate the signing of additional supply agreements and partnerships with industry-leading licensed producers, and we feel confident in the direction we are headed. It has been extremely rewarding to see the willingness of top producers and industry leaders to collaborate with Namaste in a joint effort to revolutionize the cannabis industry. Namaste’s management team looks forward to moving forward and working with Clever Leaves team to bring value to its patients.”

About Clever Leaves

Clever Leaves is a vertically-integrated licensed producer of medical cannabis.  Located in Colombia, Clever Leaves has broken ground on an industrial Good Agricultural Collection Practices (“GACP”) compliant cultivation facility and Good Manufacturing Practices (“GMP”) Level-2 Extraction facility, capable of producing up to 15,000,000 ml of cannabis oil per year.  By leveraging the highest-grade technology and practices from the international pharmaceutical and cannabis industries, Clever Leaves is positioned to lead the production of low-cost, high grade medical cannabis extracts for global exportation. For more information, visit en.cleverleaves.com

About Northern Swan

Northern Swan is a New York-based investment firm focused on early and late-stage investments in the legal cannabis industry. Northern Swan delivers a comprehensive solution for financing and advising licensed cannabis operators globally. Northern Swan’s investment professionals have collectively invested in excess of $3 billion of capital at Blackstone, KKR, and Och-Ziff.  For more information, visit www.northernswan.com

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Contacts
Namaste
On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Clever Leaves
Andrés Fajardo
Chairman
Email: [email protected]

Northern Swan
Kyle Detwiler
Chief Executive Officer
Direct: +1 (646) 880 4382
Email: [email protected]

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , ,
Posted in All Recent Posts, Featured, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Signing of a Medical Cannabis Product Acquisition Agreement With Colombian Licensed Producer Clever Leaves $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca $NXTTF Announces Non-Binding Terms Sheet With Australian-Based Medical Cannabis Company PharmaCann Pty Ltd $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:39 AM on Thursday, March 22nd, 2018

Nlogo

  • Signed a non-binding Terms Sheet with PharmaCann Pty Ltd.
  • Namaste will participate in an investment to purchase a 10% equity position in PharmaCann
  • PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health

VANCOUVER, British Columbia, March 22, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that it has signed a non-binding Terms Sheet (the “Terms Sheet”) with PharmaCann Pty Ltd. (“PharmaCann”), whereby Namaste will participate in an investment to purchase a 10% equity position in PharmaCann. PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health. Namaste’s investment in PharmaCann will be used by PharmaCann to proceed with its application to further secure a cultivation license. The Australian market represents a major component of Namaste’s current revenue, which is derived in hardware sales, and remains a primary focus of Namaste’s strategic initiatives as it looks to target the Australian medical cannabis industry. Namaste believes PharmaCann’s import, export and wholesale licenses bring immediate value to the Company and believes that  PharmaCann has the ability to obtain a cultivation license which will further enhance Namaste’s ability to penetrate global markets. In addition to Namaste’s strategic investment in PharmaCann, the Terms Sheet outlines additional business ventures between both parties as outlined below.

 

Key Terms:

  • Namaste will provide a cash investment for 10% equity in PharmaCann.
  • Namaste will purchase 250kg annually of medical cannabis for export to Canada under the Company’s wholly owned subsidiary Cannmart Inc. (“Cannmart”) for the next three years, subject to approval by Health Canada.
  • Namaste will assist PharmaCann with implementation of a global distribution strategy.
  • Namaste will provide non-exclusive access to its database of Australian consumers.
  • PharmaCann will leverage its import, export and wholesale licenses to support Namaste in international markets.
  • PharmaCann will grant up to 10% of its useable space to develop genetic strains of medical cannabis with Namaste.
  • PharmaCann will perform clinical trials with the use of Namaste’s hardware and client-base, in accordance with Australian state and federal laws.
  • Closing of the proposed agreement will be contingent upon negotiating and execution of definitive documentation and approval of the terms of the agreement by each party’s respective directors.

Namaste remains committed to focusing on opportunities and collaborations with PharmaCann in the Australian market, as it represents an important part of the Company’s growth strategy moving forward. As the Canadian market progresses closer towards full legalization, Namaste is of the opinion that additional markets, such as Australia, will provide Namaste with a more diverse market presence by allowing the Company to continue leveraging its global database of cannabis users. This strategy represents an opportunity for Namaste to expand its global ecommerce platform into other progressive markets, as it looks to replicate the success it has achieved in the Canadian market.

Management Commentary

Victor Caprio, Managing Director and CEO of PharmaCann comments: “PharmaCann is excited to be working with Namaste to strengthen our respective positions in the Australian and International Markets. With Namaste’s strategic investment in PharmaCann, we strongly believe that our current foothold in the Australian Market will be amplified exponentially and will provide us with further opportunities to increase our market offerings, whilst allowing for further growth in this exciting and ever-evolving industry. Additionally, our teams look forward to continuing our close working relationship together to ensure that our shared values and overall objectives are maintained, both now and into the future.”

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to announce this non-binding Terms Sheet with PharmaCann. This is something we have been working on for several months and having received our Canadian ACMPR license, we plan on executing our strategy to launch a similar platform in regional markets where Namaste maintains large market presence. There are a multitude of synergistic relationships with PharmaCann not only from cultivation but in leveraging PharmaCann’s import, export and wholesale licenses to expand on our global operations. We are very excited at the incredible opportunities that exist globally, as other countries look to capitalize on the rapidly growing cannabis industry.”

About PharmaCann

PharmaCann Pty Ltd is an Australian Company that was formed by a group of entrepreneurs, whom shared the same belief that medicinal cannabis can be a beneficial and viable treatment option for patients with multiple and varying conditions throughout Australia and the world. PharmaCann formed its Biotechnology and Nutraceutical Company with a team of public health and medical experts dedicated and committed to supplying an alternative to traditional medications with the use of cannabinoids. Our Medical and Allied Health Network works diligently to ensure that Patients have adequate access to alternative treatment options, whilst working closely with our State and Federal Regulatory Agencies to ensure that adequate access is maintained.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

PharmaCann Pty Ltd
“Victor Caprio”
Managing Director & CEO
Email: [email protected]

 

Further information on the Company and its products can be accessed through the links below:

 

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca
Pharmacann.com.au

 

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Non-Binding Terms Sheet With Australian-Based Medical Cannabis Company PharmaCann Pty Ltd $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Monday, March 19th, 2018

Logo tetrabiopharma rgb web

  • Announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary
  • Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders

OTTAWA, ONTARIO–(March 19, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction“) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers“).

“The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.”

The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

BREAKING: Namaste $N.ca $NXTTF Receives ACMPR Medical #Cannabis Production License $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:04 PM on Friday, March 16th, 2018

Nlogo

  • Wholly owned subsidiary, Cannmart has received its Access to Cannabis for Medical Purposes Regulations Production License
  • Cannmart may now place initial orders with ACMPR licensed producers
  • Confident in its ability to execute and complete the final steps towards receiving its Sales License in a timely manner
  • With receipt of the production license, Namaste now expects to execute on its overall vision of becoming an all-inclusive online cannabis marketplace

VANCOUVER, British Columbia, March 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) Production License (the “License”). Under the guidelines set forth by Health Canada, Cannmart may now place initial orders with ACMPR licensed producers. Upon receipt, packaging and testing of the initial shipments of medical cannabis, the Company is then required to demonstrate compliance with standard operating procedures (“SOPs”) and other ACMPR regulatory requirements with Health Canada. Once these objectives have been achieved and following an initial inspection, Cannmart will be able to book a Pre-Sales License Inspection after which the Company will be eligible to receive its ACMPR Sales License. Cannmart believes it is well prepared and confident in its ability to execute and complete the final steps towards receiving its Sales License in a timely manner.

If Cannmart receives its Sales License, Cannmart will then operate as one of the first aggregators of medical cannabis, sourced from handpicked ACMPR licensed producers. The Company has identified the need for a competitive landscape where patients have the ability to access a larger variety of medical cannabis strains and oils, without the need to change licensed producers. Through a combination of strategic service and supply agreements, Cannmart will be well-positioned to provide Canadian patients with access to a wide range of medical cannabis products through the most diverse online platform in the Canadian cannabis market. Namaste acquired Cannmart as a late-stage ACMPR applicant, with the intention of creating Canada’s most expansive marketplace for medical cannabis. The receipt of the Production License represents a significant milestone for the Company and will help to propel Namaste to become one of Canada’s leading e-commerce retailer of medical cannabis.

Namaste currently operates one of the largest global e-commerce platforms for cannabis delivery devices and plans to leverage its technology and consumer data with the end goal of acquiring medical patients. In order to facilitate growth at an accelerated rate, the Company plans to utilize its recently launched mobile application under its wholly owned subsidiary, NamasteMD Inc. (“NamasteMD”). This revolutionary medical cannabis app is Canada’s first virtual patient consultation portal to be approved by Apple and Google to be used on both iOS and Android devices. NamasteMD will serve the company as a patient acquisition tool, allowing patients to connect with doctors and nurse practitioners in a safe and secure online environment from the comfort of their homes. NamasteMD was designed to streamline the patient onboarding process in comparison to traditional brick-and-mortar clinics.

With receipt of the production license, Namaste now expects to execute on its overall vision of becoming an all-inclusive online cannabis marketplace and creating a platform that consolidates many of the best product offerings by the top ACMPR Licensed Producers in Canada. Namaste believes it can now deliver on its promise of providing patients with a true “one stop shopping” experience. Namaste will continue creating strategic partnerships through various agreements in attempt to innovate in the Canadian medical cannabis industry.

Further to this news release, Namaste will host a special edition Namaste Live420 on the Company’s YouTube channel via the link below, on Monday, March 19th, 2018 at 8:30 AM EDT to discuss and answer shareholder questions.

https://www.youtube.com/watch?v=TOGWr21c-rE&feature=youtu.be

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “This important milestone represents an incredible achievement for Namaste and its shareholders. Receipt of the ACMPR Production License not only validates Namaste’s strategy but it serves as a critical component of the Company’s anticipated growth moving forward.  We are very proud to have met our goal of receiving our ACMPR medical cannabis Production License from Health Canada as we look to explore the tremendous opportunities that exist in the Canadian cannabis market. While we are excited with this achievement, management remains highly focused on completing the final protocols set forth by Health Canada and plan on executing the final steps towards receiving our “Sales Only” License.  If the Sales Licence is received, we fully intend on leveraging our data and technology through our global network of operations where we believe we will be well-positioned to implement the same strategy in other legal markets where the Company has established strong market share.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on BREAKING: Namaste $N.ca $NXTTF Receives ACMPR Medical #Cannabis Production License $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, March 14th, 2018

Logo tetrabiopharma rgb web

  • Announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to the active ingredients of its PPP001 drug for the treatment of complex regional pain syndrome 
  • FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA
  • Gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA

OTTAWA, ONTARIO–(March 14, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.

The FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA. This designation gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA, and provides Tetra potential incentives such as access to federal grants and tax credits as well as a waiver of Prescription Drug User Fee Act filing fees.

Tetra successfully completed a placebo-controlled Phase 1a and 1b study of PPP001 in healthy volunteers and demonstrated that PPP001 can be safely consumed. “We are pleased to receive FDA Orphan Drug Designation for PPP001 and we look forward to discussing the clinical program with the US FDA that will be used to demonstrate the safety and efficacy in patients suffering from CRPS,” said Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer of Tetra.

According to the USA National Institute of Health, “complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb (arm, leg, hand, or foot) usually after an injury. CRPS is believed to be caused by damage to, or malfunction of, the peripheral and central nervous systems. CRPS is characterized by prolonged or excessive pain and changes in skin color, temperature, and/or swelling in the affected area.”

Appointment of a New Director – Tetra also announced the appointment of a new Director, Mr. Benoit Chotard, effective immediately. Mr. Chotard was previously a member of the Board of Directors from September 2016 to July 2017, he left for personal reasons, no longer applicable, and is pleased to come back. “We are glad to welcome back Mr. Chotard to the board and we look forward to working closely with him in building Tetra as a leading biopharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Mr. Chotard’s tremendous experience as an advisor of publicly listed companies will be a huge addition to our team. His local and international network will be a key factor in the Company’s growth.”

Benoit Chotard is a corporate finance & development executive who has over 20 years of international corporate finance, management and public market expertise. Previously, Mr. Chotard was employed as managing partner at Capital Force United, as President & CEO, and Director of Orletto Capital Inc., Vice-president Corporate Development for Pakit Inc., Senior Vice-president Finance Corporate Development and acting as Chief Financial Officer for CANTRONIC Systems (Canada) Inc., Vice-President Chief Financial Officer of Victhom Human Bionics, and spent eight years as Head of the Technology Investment Group of National Bank Financial Inc.

Mr. Chotard has been a Member of “Ordre des ingénieurs du Québec” since 1989 and obtained a bachelor’s degree in Chemical Engineering (1989) and a MBA (1993) from the Université de Sherbrooke.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »